SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMDl/27/2019 dated February 08, 2019, please find enclosed, the 'Annual Secretarial Compliance Report' of the Company for the year ended 31st March 2020 issued by KJB & Co. LLP, Practicing Company Secretaries, Mumbai. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Closure of Trading Window
This is to inform you that, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the Code of Conduct for Prevention of Insider Trading ('The CoC'), the Trading Window for trading by Designated Persons of the Company and their Immediate Relatives shall be closed with effect from Wednesday, 1st July 2020 till 48 hours after the declaration of financial results of the Company for the quarter ended 30th June 2020. The date of Board Meeting for declaration of the financial results for the quarter ended 30th June 2020 will be intimated in due course. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosure Of Related Party Transactions - March 2020
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended March 31, 2020. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 12, 2020 for Raksha Sudhir Valia SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Financial Results For The Quarter And Year Ended 31St March 2020
The Board of Directors of the Company at their meeting held from 06:30 pm to 08:30 pm today, inter alia, took on record and duly approved the Audited Financial Results for the quarter and year ended 31st March, 2020 which are enclosed along with the Auditors' Report on the Financial Statements of the Company for the financial year ended 31st March 2020, as Annexure 1. In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2020 is also enclosed as Annexure 2. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of Directors of the Company at their meeting held today from 04:45 pm to 09:15 pm, inter alia, appointed Dr. Robert Spiegel (DIN: 0008739625) as Additional Director (Independent) of the Company to hold office up to the ensuing Annual General Meeting of the Company. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release being released by the Company, which is self-explanatory. We request you to kindly take the same on record. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Intimation for Notice Of Board Meeting For Consideration Of Audited Results Of The Company For The Fourth Quarter And Financial Year Ended 31St March 2020.
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2020 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Tuesday, 2nd June 2020, inter alia, to consider and approve, the audited financial results of the Company for the fourth quarter and financial year ended 31st March 2020. In view of the above and pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 4th June 2020 i.e. 48 hours after the declaration of financial results of the Company on 2nd June 2020. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Submission Of Compliance Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
As per the requirements of Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate issued by M/s. Veenit Pal & Associates, Practicing Company Secretaries, for the half year ended 31st March 2020.